Feasibility of molecular testing in a multicenter study with geographical variation in India: Epidermal growth factor receptor mutation as a model molecular test

Feasibility of molecular testing in a multicenter study with geographical variation in India: Epidermal growth factor receptor mutation as a model molecular test

Context: Trends in epidermal growth factor receptor (EGFR) mutation based on ethnicity assist the initial selection of targeted therapy regimen. Reported incidence of EGFR mutation in Indian NSCLC patients is variable, ranging from 22% to 51.8%. Aim and Settings and Design: This multicent...

Full description

Bibliographic Details
Main Authors:	Kumar Prabhash, Amit Rauthan, Senthil Rajappa, Chirag Desai, Rajesh Mistry, Amit Dutt, Anuradha Chougule, Ravi Mohan, Pratap K Das, Rajiv Kumar, Vanita Noronha, Amit Joshi, Vijay M Patil, Binay Swarup, Anil Kukreja
Format:	Article
Language:	English
Published:	Thieme Medical Publishers, Inc. 2017-01-01
Series:	Asian Journal of Oncology
Subjects:	epidermal growth factor receptor mutation nonsmall cell lung cancer tyrosine kinase inhibitor india
Online Access:	http://www.thieme-connect.de/DOI/DOI?10.4103/ASJO.ASJO_104_16

Similar Items

Third-line therapy in the epidermal growth factor receptor mutation-positive advanced nonsmall-cell lung cancer
by: Vanita Noronha, et al.
Published: (2020-01-01)

Molecular biology of head and neck cancers
by: Deepa Philip, et al.
Published: (2016-01-01)

Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line – Indian consensus statement update
by: Kumar Prabhash
Published: (2019-01-01)

Molecular tumor board: Case 2 – Evolution of resistance in anaplastic lymphoma kinase driven non-small-cell lung carcinoma
by: Akhil Kapoor, et al.
Published: (2020-01-01)

Authors' reply to Raja and Suryavanshi
by: Anuradha Chougule, et al.
Published: (2020-01-01)

Resistance mechanisms to epidermal growth factor receptor inhibitors in non-small cell lung cancer
by: Suresh Kumar Bondili, et al.
Published: (2020-01-01)

Molecular tumor board: Case 1-Interplay of EGFR, MET and PD-L1 in non-small cell lung carcinoma
by: Akhil Kapoor, et al.
Published: (2019-01-01)

Frequency of EGFR mutations in 907 lung adenocarcioma patients of Indian ethnicity.
by: Anuradha Chougule, et al.
Published: (2013-01-01)

EGFR mutations in Indian lung cancer patients: clinical correlation and outcome to EGFR targeted therapy.
by: Vanita Noronha, et al.
Published: (2013-01-01)

Association between thyroid cancer and epidermal growth factor receptor mutation in female with nonsmall cell lung cancer
by: Seo Yun Kim, et al.
Published: (2017-01-01)

Authors' reply to Devakumar et al., Katte et al., and Batra et al.
by: Suresh Kumar Bondili, et al.
Published: (2021-01-01)

Role of gender in the survival of surgical patients with nonsmall cell lung cancer
by: Nóris C Scaglia, et al.
Published: (2013-01-01)

Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management
by: Akhil Rajendra, et al.
Published: (2019-01-01)

Crizotinib-Associated Renal Cysts: A Case Series
by: Garima Suman, et al.
Published: (2019-07-01)

Weekly osimertinib dosing prevents EGFR mutant tumor cells destined to home mouse lungs
by: Ashwin Butle, et al.
Published: (2021-08-01)

Coexistence of epidermal growth factor receptor mutation and anaplastic lymphoma kinase translocation in non-small cell lung cancer: Do we know the treatment sequence?
by: Vikas T Talreja, et al.
Published: (2019-01-01)

Molecular epidemiological study of microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene using immunohistochemistry as a cost effective alternative to fluorescence in situ hybridization for Indian patients with adenocarcinoma lung
by: Anurag Mehta, et al.
Published: (2017-01-01)

The clinical outcome of brain metastases in nonsmall cell lung cancer patients with epidermal growth factor receptor mutation- A retrospective single-institution analysis
by: Cho-Hao Lee, et al.
Published: (2018-01-01)

Authors' reply to Dubey et al. and Bhattacharyya et al.
by: Akhil Kapoor, et al.
Published: (2020-01-01)

Patterns of epidermal growth factor receptor testing across 111 tertiary care centers in India: Result of a questionnaire-based survey
by: Kumar Prabhash, et al.
Published: (2018-01-01)

Pertuzumab: Unprecedented benefit in human epidermal growth factor receptor 2-positive breast cancer
by: Amit Rauthan, et al.
Published: (2015-07-01)

Large apical lung cancer treated with CT-guided percutaneous cryoablation
by: Benedicta Mutiara Suwita, et al.
Published: (2024-04-01)

Association between Mortality and Lung Low Attenuation Areas in NSCLC Treated by Surgery
by: Davide Colombi, et al.
Published: (2023-06-01)

Comorbidities with non-small cell lung cancer: Is there an interdisciplinary consensus needed to qualify patients for surgical treatment?
by: Marta Lembicz, et al.
Published: (2018-01-01)

Identifying Prognostic Groups Using Machine Learning Tools in Patients Undergoing Chemoradiation for Inoperable Locally Advanced Nonsmall Cell Lung Carcinoma
by: Anjali K. Pahuja, et al.
Published: (2019-07-01)

Authors' reply to Vora et al. and Singh et al.
by: Akhil Kapoor, et al.
Published: (2020-01-01)

Elucidating the mechanisms of resistance to tyrosine kinase inhibitors in lung cancer patients
by: Asim Joshi, et al.
Published: (2017-10-01)

Evaluation of Three Small Molecular Drugs for Targeted Therapy to Treat Nonsmall Cell Lung Cancer
by: Jun Ni, et al.
Published: (2016-01-01)

Authors' reply to Batra et al., Chadha et al., and Deb et al.
by: Akhil Kapoor, et al.
Published: (2020-01-01)

Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of a Phase III randomized trial to compare the benefit of gefitinib versus pemetrexed/carboplatin for epidermal growth factor receptor-mutated non-small cell lung cancer
by: Vijay Patil, et al.
Published: (2019-01-01)

Efficacy of paclitaxel‐carboplatin with bevacizumab as a late‐line therapy for patients with advanced nonsquamous non‐small cell lung cancer: A platinum rechallenge
by: Jun Sugisaka, et al.
Published: (2023-11-01)

Lorlatinib‐induced visual and auditory hallucinations: A case report
by: Jun Hakamata, et al.
Published: (2021-08-01)

Analysis of adverse drug reactions of Osimertinib in the 2nd‐line treatment of EGFR mutant advanced nonsmall cell lung cancer
by: Yingying Jiang, et al.
Published: (2022-06-01)

Authors' response to Vora and Rajpurohit
by: Vanita Noronha, et al.
Published: (2020-01-01)

Association of Immune-Related Adverse Effects and Survival in Solid Tumor Patients Treated with PD1 Inhibitors
by: Akhil Kapoor, et al.
Published: (2022-10-01)

Impact of Molecular Tumor Board on the Clinical Management of Patients With Cancer
by: Vichitra Behel, et al.
Published: (2022-07-01)

Frequency of T790M mutations after progression on epidermal growth factor receptor tyrosine kinase inhibitor in metastatic non-small cell lung cancer in Indian patients: real-time data from tertiary cancer hospital
by: Venkata Pradeep Babu Koyyala, et al.
Published: (2018-01-01)

Sequential treatment with alectinib in crizotinib-resistant non-small-cell lung cancer
by: Swaratika Majumdar, et al.
Published: (2018-01-01)

Authors' reply to Krishnamurthy et al.
by: Goutam Santosh Panda, et al.
Published: (2022-01-01)

Epidermal growth factor receptor mutations in nonsmall cell lung carcinoma patients in Kuwait
by: Rabeah Al-Temaimi, et al.
Published: (2016-01-01)